Drug Trial Radar · NCT06780085
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
May 13, 2025
Primary completion
Mar 12, 2032
Study completion Mar 12, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Raludotatug DeruxtecanBiological
IV Infusion
Ifinatamab DeruxtecanBiological
IV Infusion
DocetetaxelDrug
IV Infusion
5-hydroxytryptamine subtype 3 receptor antagonistDrug
Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion
Neurokinin-1 receptor antagonistDrug
Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion
CorticosteroidDrug
Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion, and for 3 days starting 1 day prior to docetaxel administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to approximately 81 months
- Percentage of Participants with at Least One Adverse Event (AE)Time frame: Up to approximately 81 months
- Percentage of Participants Who Discontinued Medication Due to an AETime frame: Up to approximately 24 months
Locations
36 sites in 10 countries. Site status is shown where the registry gives one.
University of Kentucky Chandler Medical Center ( Site 0019)
Lexington, Kentucky
MedStar Franklin Square Medical Center ( Site 0033)
Baltimore, Maryland
AHN Cancer Institute - Allegheny General ( Site 9501)
Pittsburgh, Pennsylvania
Texas Oncology - DFW ( Site 8003)
Dallas, Texas
Centro de Estudios Clínicos SAGA ( Site 0161)
Santiago, Region M. de Santiago, Chile
Fundación Arturo López Pérez ( Site 0160)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0162)
Santiago, Region M. de Santiago, Chile
Charite-Universitaetsmedizin Berlin ( Site 0191)
Berlin, Germany
Universitaetsklinik Tuebingen ( Site 0192)
Tübingen, Baden-Wurttemberg, Germany
European Interbalkan Medical Center ( Site 0205)
Thessaloniki, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 0204)
Athens, Attica, Greece
Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 0063)
Kecskemét, Bács-Kiskun county, Hungary
Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)
Győr, Győr-Moson-Sopron, Hungary
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Református Pulmonológiai Centrum ( Site 0064)
Törökbálint, Pest County, Hungary
Rambam Health Care Campus ( Site 0076)
Haifa, Israel
Shaare Zedek Medical Center ( Site 0075)
Jerusalem, Israel
Meir Medical Center ( Site 0071)
Kfar Saba, Israel
Rabin Medical Center ( Site 0074)
Petah Tikva, Israel
Sheba Medical Center ( Site 0070)
Ramat Gan, Israel
Sourasky Medical Center ( Site 0077)
Tel Aviv, Israel
Azienda Ospedaliera Universitaria Careggi ( Site 0173)
Florence, Italy
Ospedale San Raffaele. ( Site 0171)
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)
Roma, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)
Milan, Lombardy, Italy
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0153)
Poznan, Greater Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdansk, Pomeranian Voivodeship, Poland
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0152)
Koszalin, West Pomeranian Voivodeship, Poland
Hospital Universitario Quiron Madrid ( Site 0091)
Madrid, Spain
Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
L'Hospitalet de Llobregat, Barcelona, Spain
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 0141)
Adana, Turkey (Türkiye)
Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0140)
Ankara, Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi. ( Site 0142)
Ankara, Turkey (Türkiye)
I. U. Cerrahpasa Tip Fakultesi ( Site 0144)
Istanbul, Turkey (Türkiye)
Ege Universitesi Hastanesi ( Site 0143)
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.